Jaguar Health (JAGX) CSO receives 11,740 RSUs and 11,740 options

Q: What insider stock awards did Jaguar Health (JAGX) report in this filing?

The filing reports that Chief Scientific Officer Pravin Chaturvedi received 11,740 restricted stock units of Jaguar Health voting common stock and a stock option for 11,740 shares at an exercise price of $1.44 per share, both granted on December 11, 2025 .

Q: Who is the reporting person in the Jaguar Health (JAGX) insider transaction?

The reporting person is Pravin Chaturvedi , who serves as Chief Scientific Officer of Jaguar Health, Inc. He is identified as an officer of the issuer and not as a director or 10% owner.

Q: What are the key terms of the Jaguar Health (JAGX) stock options granted?

The filing shows a stock option (right to buy) covering 11,740 shares of Jaguar Health common stock with an exercise price of $1.44 per share and an expiration date of December 11, 2035 . The options will vest ratably on a monthly basis over 12 months from the grant date , as long as the executive remains employed by Jaguar Health.

Q: Under what plan were the Jaguar Health (JAGX) equity awards granted?

The restricted stock units and stock option were granted pursuant to Jaguar Health’s 2014 Stock Incentive Plan , as stated in the explanation of responses section.

Q: What reverse stock split did Jaguar Health (JAGX) complete in 2025?

The filing notes that on March 24, 2025 , Jaguar Health effected a 25-for-1 reverse stock split of its issued and outstanding voting common stock, so that every 25 shares were automatically converted into one share of voting common stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Jaguar Health Chief Scientific Officer Pravin Chaturvedi reported new equity awards in the company’s stock. On December 11, 2025, he received 11,740 restricted stock units, each representing a right to one share of Jaguar Health voting common stock. These restricted stock units vest on December 11, 2026, when the underlying shares are scheduled to be delivered.

On the same date, he was also granted a stock option covering 11,740 shares of common stock at an exercise price of $1.44 per share, expiring on December 11, 2035. The option vests ratably on a monthly basis over 12 months from the grant date, as long as he remains employed, and both awards were granted under Jaguar Health’s 2014 Stock Incentive Plan. Following the grant, he beneficially owned 11,938 shares of common stock directly, plus the 11,740 stock options. The filing also notes a 25-for-1 reverse stock split of Jaguar’s voting common stock effective March 24, 2025.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Chaturvedi Pravin R

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	11,740	$0.00	--
Grant/Award	Common Stock	11,740	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 11,740 shares (Direct); Common Stock — 11,938 shares (Direct)

Footnotes (1)

Granted pursuant to the issuer's 2014 Stock Incentive Plan. The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025. Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice. On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split"). Upon effectiveness of the Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock. The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer.

Form 4 Insider Transactions: What Each Field Means →

12/15/2025 - 06:02 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chaturvedi Pravin R

(Last)

(First)

(Middle)

C/O JAGUAR HEALTH, INC.

200 PINE ST., STE 400

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Jaguar Health, Inc. [ JAGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock⁽¹⁾	12/11/2025⁽²⁾⁽³⁾		A		11,740	A	$0	11,938⁽⁴⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)⁽¹⁾	$1.44	12/11/2025⁽²⁾		A		11,740		⁽⁵⁾	12/11/2035	Common Stock	11,740	$0	11,740	D

Explanation of Responses:

1. Granted pursuant to the issuer's 2014 Stock Incentive Plan.

2. The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.

3. Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice.

4. On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split"). Upon effectiveness of the Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock.

5. The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer.

	/s/ Chaturvedi Pravin	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider stock awards did Jaguar Health (JAGX) report in this filing?

The filing reports that Chief Scientific Officer Pravin Chaturvedi received 11,740 restricted stock units of Jaguar Health voting common stock and a stock option for 11,740 shares at an exercise price of $1.44 per share, both granted on December 11, 2025.

Who is the reporting person in the Jaguar Health (JAGX) insider transaction?

The reporting person is Pravin Chaturvedi, who serves as Chief Scientific Officer of Jaguar Health, Inc. He is identified as an officer of the issuer and not as a director or 10% owner.

How do the restricted stock units for Jaguar Health (JAGX) vest?

Each restricted stock unit represents a contingent right to receive one share of Jaguar Health voting common stock. The 11,740 restricted stock units vest on December 11, 2026, and vested shares are scheduled to be delivered to the reporting person on the vesting date provided in the grant notice.

What are the key terms of the Jaguar Health (JAGX) stock options granted?

The filing shows a stock option (right to buy) covering 11,740 shares of Jaguar Health common stock with an exercise price of $1.44 per share and an expiration date of December 11, 2035. The options will vest ratably on a monthly basis over 12 months from the grant date, as long as the executive remains employed by Jaguar Health.

How many Jaguar Health (JAGX) shares does the insider own after these grants?

After the reported transactions, the reporting person beneficially owned 11,938 shares of Jaguar Health common stock directly, as well as 11,740 stock options as derivative securities.

Under what plan were the Jaguar Health (JAGX) equity awards granted?

The restricted stock units and stock option were granted pursuant to Jaguar Health’s 2014 Stock Incentive Plan, as stated in the explanation of responses section.

What reverse stock split did Jaguar Health (JAGX) complete in 2025?

The filing notes that on March 24, 2025, Jaguar Health effected a 25-for-1 reverse stock split of its issued and outstanding voting common stock, so that every 25 shares were automatically converted into one share of voting common stock.